A new study finds that large-scale human trials of new treatments in medicine have the potential to pay rich dividends-huge economic benefits from improved quality of life.
S. Claiborne Johnston and his colleagues at the University of California, San Francisco evaluated all 28 trials that the National Institute of Neurological Diseases and Stroke (NINDS) in Bethesda, Md.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.